Compare Shell PLC (SHEL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Sanofi SA — how do they compare? Shell PLC trades at $100.36 (market cap $284.34B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Shell PLC is far larger — about 3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and Sanofi SA for 94 Days on average.
| SHEL | SNY | |
|---|---|---|
Market Cap | $284.34B | $95.18B |
Volume | 9,097,469 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $100.20 | $52.34 |
52-Week Low | $70.31 | $39.51 |
Typical Hold Time | 90 Days | 94 Days |
Enterprise Value | $326.04B | $114.48B |
Dividend Yield | 3.12% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $100.18, up 3.44% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.08, ROE of 14.35%, and recent earnings beats. Recent developments include the LNG Canada Phase 2 expansion approval, doubling export capacity, positioning Shell for long-term LNG growth. Cash flow remains healthy despite a temporary net outflow in 2025.
Shell presents a compelling investment case with attractive valuation, strong profitability, and strategic LNG expansion. Risks include revenue volatility from oil prices and execution challenges in major projects. Analyst consensus is bullish with a $102.53 price target, suggesting modest upside from current levels.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
